Abhi Yalamanchili

The Institutional Biosafety Committee reviewed and discussed several research protocols, including renewals and amendments regarding microbial modulation, RNA-based therapeutics, and host-pathogen interactions. Key topics included the use of various viral vectors, CRISPR-mediated gene editing in different cell lines and animal models, and safety protocols for BSL-2 and BSL-3 facilities. The committee also addressed information regarding the movement of large animals between research facilities and received updates on clinical study protocols for immunotherapies and pneumococcal pneumonia research.

The committee reviewed reports on incidents involving EHS, including needlesticks and bites, and discussed the status of various open accidents. Several research protocols were reviewed, discussed, and voted on, covering topics such as gene silencing therapeutics for ALS-FUS, SARS-CoV-2 biocontainment level adjustments, gut microbiome research, axonal injury in mice, translational epigenetics using genomic editing, and fetal cell isolation methods. Additionally, the meeting included updates on BSL-3 and ABSL-3 facility improvements, information on chemical safety, a discussion on biohazard waste disposal, and updates on ongoing clinical trial protocols.

The committee reviewed reports on incidents and accidents from Employee Health Services, including both past and recent BSL-3 laboratory exposures and animal-related incidents. Eleven research protocols were discussed, covering studies on RNA structure, CAR T-cell therapy for systemic lupus erythematosus, metabolic disease, stress response signaling pathways, T cell activation, innate immune responses, translational control, immune responses to pathogens and cancers, and protein/antibody generation. Most protocols were approved pending completion of specified action items regarding experimental methodology and biosafety clarifications. Additionally, the meeting addressed BSL-3 and ABSL-3 facility status and safety design plans.

The committee reviewed several research protocols involving adeno-associated virus gene therapy, mouse models for retinal research, and metalloproteinase function. Discussions addressed biosafety levels, viral vector production processes, and necessary training or documentation for protocol approvals. Additionally, the committee discussed a CDC inspection response regarding ABSL-3 personal protective equipment requirements and procedures, reviewed updates to the Biosafety Manual, and received reports on facility permitting and decontamination status.

This document, 'IMPACT 2025', outlines UMass Chan Medical School's strategic roadmap to advance health and wellness across diverse communities globally. It is structured around six strategic pillars: Education, Basic Science, Translational Research, Community and Global Impact, Operational Excellence and Financial Stewardship, and Diversity, Equity and Inclusion. The plan aims to establish the institution as a leading-edge medical school, known for an enhanced social mission and significant contributions.